CD19 and non-Hodgkin lymphoma: Another phase 1 study (NCT04036019) indicated that in patients with R/R non-Hodgkin lymphoma who failed anti-CD19 CAR T therapy, the use of an anti-CD20 CAR construct was safe in that 86% of patients experienced only grade 1 or 2 CRS with no severe neurotoxicity [34].